About Seres Therapeutics (NASDAQ:MCRB)
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:MCRB
- CUSIP: N/A
- Web: www.serestherapeutics.com
Capitalization:- Market Cap: $416.02 million
- Outstanding Shares: 40,513,000
Average Prices:- 50 Day Moving Avg: $13.48
- 200 Day Moving Avg: $13.48
- 52 Week Range: $8.85 - $17.42
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.58
- P/E Growth: 0.03
Sales & Book Value:- Annual Revenue: $22.08 million
- Price / Sales: 18.31
- Book Value: $2.18 per share
- Price / Book: 4.58
Profitability:- EBITDA: ($92,650,000.00)
- Net Margins: -441.38%
- Return on Equity: -80.21%
- Return on Assets: -37.80%
Debt:- Debt-to-Equity Ratio: 0.11%
- Current Ratio: 6.86%
- Quick Ratio: 6.86%
Misc:- Average Volume: 275,466 shs.
- Beta: 0.37
- Short Ratio: 14.18
Frequently Asked Questions for Seres Therapeutics (NASDAQ:MCRB)
What is Seres Therapeutics' stock symbol?
Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."
How were Seres Therapeutics' earnings last quarter?
Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.69) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.59) by $0.10. The company had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company's quarterly revenue was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. View Seres Therapeutics' Earnings History.
When will Seres Therapeutics make its next earnings announcement?
Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?
9 analysts have issued 12 month target prices for Seres Therapeutics' shares. Their predictions range from $16.00 to $20.00. On average, they anticipate Seres Therapeutics' stock price to reach $18.75 in the next year. View Analyst Ratings for Seres Therapeutics.
What are analysts saying about Seres Therapeutics stock?
Here are some recent quotes from research analysts about Seres Therapeutics stock:
- 1. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (10/11/2017)
- 2. Cowen and Company analysts commented, "Seres reported top-line results from a Phase 1b trial of SER-287 in 58 patients with." (10/2/2017)
- 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)
Who are some of Seres Therapeutics' key competitors?
Some companies that are related to Seres Therapeutics include Reata Pharmaceuticals (RETA), ZIOPHARM Oncology (ZIOP), Revance Therapeutics (RVNC), Cytokinetics, Incorporated (CYTK), Alder BioPharmaceuticals (ALDR), La Jolla Pharmaceutical Company (LJPC), Keryx Biopharmaceuticals (KERX), CytomX Therapeutics (CTMX), PTC Therapeutics (PTCT), Vanda Pharmaceuticals (VNDA), Coherus BioSciences (CHRS), Aclaris Therapeutics (ACRS), Audentes Therapeutics (BOLD), Dova Pharmaceuticals (DOVA), Aduro Biotech (ADRO), MacroGenics (MGNX), Paratek Pharmaceuticals (PRTK) and Synergy Pharmaceuticals (SGYP).
Who are Seres Therapeutics' key executives?
Seres Therapeutics' management team includes the folowing people:
- Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
- Eric D. Shaff, Chief Financial Officer, Executive Vice President
- John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
- David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
- Thomas J. DesRosier J.D., Chief Legal Officer, Executive Vice President and Secretary
- Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
- Noubar B. Afeyan, Lead Independent Director
- Willard H. Dere M.D., Director
- Dennis A. Ausiello M.D., Independent Director
- Gregory Behar, Independent Director
When did Seres Therapeutics IPO?
(MCRB) raised $101 million in an IPO on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.
How do I buy Seres Therapeutics stock?
Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seres Therapeutics' stock price today?
One share of Seres Therapeutics stock can currently be purchased for approximately $9.98.
MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $18.75 (87.88% upside) |
Consensus Price Target History for Seres Therapeutics (NASDAQ:MCRB)
Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/13/2017 | CIBC | Initiated Coverage | Outperform -> Outperform | $19.00 | N/A |  |
| 10/12/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Outperform | $19.00 | N/A | |
| 10/12/2017 | Citigroup Inc. | Initiated Coverage | Outperform -> Positive | $19.00 | N/A | |
| 10/6/2017 | Seaport Global Securities | Reiterated Rating | Buy | $20.00 | N/A | |
| 10/2/2017 | Cowen and Company | Reiterated Rating | Buy | | High | |
| 8/30/2017 | Cantor Fitzgerald | Reiterated Rating | Buy | | Low | |
| 8/4/2017 | HC Wainwright | Reiterated Rating | Buy -> Buy | $15.00 -> $19.00 | High | |
| 8/3/2017 | Canaccord Genuity | Set Price Target | Buy | $20.00 | Low | |
| 3/20/2017 | FBR & Co | Reiterated Rating | Outperform | $18.00 | Low | |
| 8/11/2016 | Leerink Swann | Reiterated Rating | Buy | $12.00 | N/A | |
| 8/1/2016 | Bank of America Corporation | Downgrade | Buy -> Neutral | | N/A | |
| 3/3/2016 | Guggenheim | Initiated Coverage | Buy | $41.00 | N/A | |
| 2/22/2016 | Goldman Sachs Group Inc | Lower Price Target | | $35.00 -> $34.00 | N/A | |
(Data available from 10/21/2015 forward)
Earnings History for Seres Therapeutics (NASDAQ:MCRB)Earnings History by Quarter for Seres Therapeutics (NASDAQ MCRB)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/8/2017 | | ($0.39) | | | | | N/A | |
| 8/3/2017 | Q2 2017 | ($0.59) | ($0.69) | $3.00 million | $3.00 million | View | Listen | |
| 5/4/2017 | Q1 2017 | ($0.65) | ($0.63) | $3.00 million | $3.02 million | View | Listen | |
| 3/16/2017 | Q4 2016 | ($0.70) | ($0.63) | $3.00 million | $3.00 million | View | N/A | |
| 11/10/2016 | Q316 | ($0.55) | ($0.46) | $10.38 million | $13.02 million | View | Listen | |
| 8/11/2016 | Q216 | ($0.46) | ($0.70) | $4.20 million | $3.00 million | View | Listen | |
| 5/16/2016 | Q116 | ($0.48) | ($0.50) | $1.25 million | $2.71 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.32) | ($0.38) | | | View | Listen | |
| 8/6/2015 | Q215 | ($0.30) | ($1.45) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)2017 EPS Consensus Estimate: ($2.34)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.73) | ($0.53) | ($0.63) |
| Q2 2017 | 2 | ($0.61) | ($0.50) | ($0.56) |
| Q3 2017 | 2 | ($0.66) | ($0.23) | ($0.45) |
| Q4 2017 | 2 | ($0.74) | ($0.68) | ($0.71) |
(Data provided by Zacks Investment Research)
Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Seres Therapeutics (NASDAQ:MCRB)Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 74.76%
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/29/2016 | John G Aunins | Insider | Sell | 9,390 | $10.87 | $102,069.30 | |
| 7/28/2016 | Michele Trucksis | Insider | Sell | 4,156 | $35.18 | $146,208.08 | |
| 7/27/2016 | Michele Trucksis | Insider | Sell | 38,064 | $35.14 | $1,337,568.96 | |
| 7/25/2016 | John G Aunins | Insider | Sell | 9,390 | $34.18 | $320,950.20 | |
| 7/6/2016 | Roger Pomerantz | CEO | Sell | 88,211 | $29.45 | $2,597,813.95 | |
| 7/1/2016 | Roger Pomerantz | CEO | Sell | 56,789 | $29.81 | $1,692,880.09 | |
| 6/30/2016 | Eric D Shaff | CFO | Sell | 4,533 | $29.54 | $133,904.82 | |
| 6/28/2016 | Eric D Shaff | CFO | Sell | 5,001 | $28.28 | $141,428.28 | |
| 6/27/2016 | John G Aunins | EVP | Sell | 9,390 | $27.23 | $255,689.70 | |
| 6/2/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | |
| 6/2/2016 | Roger Pomerantz | CEO | Sell | 74,049 | $32.52 | $2,408,073.48 | |
| 6/1/2016 | David N Cook | EVP | Sell | 16,000 | $29.43 | $470,880.00 | |
| 6/1/2016 | Roger Pomerantz | CEO | Sell | 70,951 | $30.51 | $2,164,715.01 | |
| 5/25/2016 | Ventures Fund 2007 L Flagship | Major Shareholder | Sell | 1,000,000 | $27.60 | $27,600,000.00 | |
| 5/24/2016 | Roger Pomerantz | CEO | Sell | 9,801 | $30.00 | $294,030.00 | |
| 5/6/2016 | Roger Pomerantz | CEO | Sell | 8,507 | $24.31 | $206,805.17 | |
| 5/5/2016 | Roger Pomerantz | CEO | Sell | 59,325 | $26.13 | $1,550,162.25 | |
| 5/3/2016 | Roger Pomerantz | CEO | Sell | 67,367 | $28.70 | $1,933,432.90 | |
| 4/25/2016 | John G Aunins | EVP | Sell | 18,640 | $31.94 | $595,361.60 | |
| 4/7/2016 | David N Cook | EVP | Sell | 8,000 | $31.00 | $248,000.00 | |
| 4/7/2016 | Roger Pomerantz | CEO | Sell | 9,212 | $30.00 | $276,360.00 | |
| 4/4/2016 | David N Cook | EVP | Sell | 61,000 | $26.16 | $1,595,760.00 | |
| 4/4/2016 | Eric D Shaff | CFO | Sell | 6,568 | $28.85 | $189,486.80 | |
| 4/4/2016 | Roger Pomerantz | CEO | Sell | 135,788 | $27.20 | $3,693,433.60 | |
| 3/31/2016 | Eric D Shaff | CFO | Sell | 7,663 | $26.30 | $201,536.90 | |
| 3/28/2016 | Eric D Shaff | CFO | Sell | 5,473 | $24.07 | $131,735.11 | |
| 3/28/2016 | John G Aunins | EVP | Sell | 9,390 | $23.89 | $224,327.10 | |
(Data available from 1/1/2013 forward)
Headline Trends for Seres Therapeutics (NASDAQ:MCRB)
Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
| Source: |
|
| Date | Headline |
|---|
 | ETFs with exposure to Seres Therapeutics, Inc. : October 17, 2017
finance.yahoo.com - October 18 at 6:52 AM |
 | $18.01 Million in Sales Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - October 18 at 1:48 AM |
 | Benzinga's Top Upgrades, Downgrades For October 13, 2017 - Benzinga
www.benzinga.com - October 14 at 2:51 AM |
| Seres Therapeutics, Inc. (MCRB) Research Coverage Started at CIBC
www.americanbankingnews.com - October 13 at 10:22 AM |
| Seres Therapeutics, Inc. (MCRB) Coverage Initiated by Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 12 at 6:26 PM |
| Seres Therapeutics, Inc. (MCRB) Earns Positive Rating from Analysts at Citigroup Inc.
www.americanbankingnews.com - October 12 at 5:18 PM |
| Seaport Global Securities Begins Coverage on Seres Therapeutics, Inc. (MCRB)
www.americanbankingnews.com - October 7 at 2:58 PM |
| Seres Therapeutics, Inc. (MCRB) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 7 at 4:52 AM |
 | Seres Therapeutics Inc. (MCRB) Tumbled To A 2-Month Low On Study Results
www.rttnews.com - October 3 at 10:23 AM |
| Seres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : October 3, 2017
finance.yahoo.com - October 3 at 10:23 AM |
| How Should You Think About Seres Therapeutics Inc’s (MCRB) Risks?
finance.yahoo.com - October 2 at 10:20 PM |
| Seres Therapeutics, Inc. (MCRB) Stock Rating Reaffirmed by Cowen and Company
www.americanbankingnews.com - October 2 at 9:32 PM |
 | Seres Therapeutics (MCRB) Says It's 'Extremely Pleased' with ... - StreetInsider.com
www.streetinsider.com - October 2 at 5:17 PM |
 | Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment
www.thestreet.com - October 2 at 11:59 AM |
 | Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
www.nasdaq.com - October 2 at 11:59 AM |
 | Seres Therapeutics stock drops 19% on clinical trial results
www.marketwatch.com - October 2 at 11:59 AM |
| CORRECTING and REPLACING Seres Therapeutics Reports Positive Topline Results from SER-287 Phase 1b Study in Patients with Ulcerative Colitis
finance.yahoo.com - October 2 at 11:59 AM |
| Analysts Expect Seres Therapeutics, Inc. (MCRB) Will Announce Quarterly Sales of $23.01 Million
www.americanbankingnews.com - September 30 at 9:50 AM |
 | Seres Therapeutics Is Hiding A Volatile Catalyst - Seeking Alpha
seekingalpha.com - September 24 at 1:12 AM |
| ETFs with exposure to Seres Therapeutics, Inc. : September 22, 2017
finance.yahoo.com - September 23 at 8:05 AM |
| Seres Therapeutics, Inc. :MCRB-US: Earnings Analysis: Q2, 2017 By the Numbers : September 20, 2017
finance.yahoo.com - September 21 at 6:00 PM |
| Seres Therapeutics, Inc. (MCRB) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - September 12 at 4:40 AM |
| Analysts Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Quarterly Sales of $23.01 Million
www.americanbankingnews.com - September 11 at 10:50 AM |
| -$0.24 EPS Expected for Seres Therapeutics, Inc. (MCRB) This Quarter
www.americanbankingnews.com - September 9 at 11:50 AM |
| Seres Therapeutics to Present at the Baird 2017 Global Healthcare Conference
finance.yahoo.com - September 1 at 3:52 AM |
| Seres Therapeutics, Inc. (MCRB) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - August 31 at 7:34 PM |
| Seres Therapeutics (MCRB) & Ophthotech Corporation (OPHT) Head to Head Comparison
www.americanbankingnews.com - August 30 at 12:22 AM |
| Seres Therapeutics, Inc. (MCRB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 18 at 4:40 AM |
| FY2017 Earnings Forecast for Seres Therapeutics, Inc. (NASDAQ:MCRB) Issued By Cantor Fitzgerald
www.americanbankingnews.com - August 10 at 10:42 AM |
| Leerink Swann Research Analysts Increase Earnings Estimates for Seres Therapeutics, Inc. (NASDAQ:MCRB)
www.americanbankingnews.com - August 7 at 7:40 AM |
| Seres Therapeutics, Inc. (NASDAQ:MCRB) Expected to Post Quarterly Sales of $3.00 Million
www.americanbankingnews.com - August 5 at 7:14 AM |
| HC Wainwright Increases Seres Therapeutics, Inc. (NASDAQ:MCRB) Price Target to $19.00
www.americanbankingnews.com - August 4 at 10:36 AM |
 | Seres Therapeutics Reports Second Quarter 2017 Financial Results ... - Business Wire (press release)
www.businesswire.com - August 4 at 1:27 AM |
| Investor Network: Seres Therapeutics Inc to Host Earnings Call
finance.yahoo.com - August 4 at 1:27 AM |
| Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress
finance.yahoo.com - August 4 at 1:27 AM |
| Seres Therapeutics reports 2Q loss
finance.yahoo.com - August 4 at 1:27 AM |
| Edited Transcript of MCRB earnings conference call or presentation 3-Aug-17 12:00pm GMT
finance.yahoo.com - August 4 at 1:27 AM |
| Seres Therapeutics, Inc. (MCRB) Issues Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - August 3 at 8:52 PM |
| Seres Therapeutics, Inc. (NASDAQ:MCRB) PT Set at $20.00 by Canaccord Genuity
www.americanbankingnews.com - August 3 at 7:20 PM |
| Brokerages Expect Seres Therapeutics, Inc. (NASDAQ:MCRB) Will Announce Earnings of -$0.59 Per Share
www.americanbankingnews.com - August 3 at 2:20 PM |
| Seres Therapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
finance.yahoo.com - August 3 at 4:44 AM |
| Seres Therapeutics to Host Second Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2017
finance.yahoo.com - July 28 at 3:38 AM |
| Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 24 at 10:54 AM |
| Seres Therapeutics (MCRB) Catches Eye: Stock Gains 9.2%
finance.yahoo.com - July 22 at 6:22 AM |
| Brokerages Anticipate Seres Therapeutics, Inc. (MCRB) Will Post Earnings of -$0.57 Per Share
www.americanbankingnews.com - July 12 at 8:44 AM |
 | BRIEF-Seres Therapeutics says size of board increased from 7 to 8
www.reuters.com - July 11 at 1:22 AM |
| Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer
finance.yahoo.com - July 11 at 1:22 AM |
| Seres Therapeutics: This Time, Success? - Seeking Alpha
seekingalpha.com - June 20 at 3:31 AM |
| XLRN's DART Misses Mark, RGLS Makes Cuts In Pipeline, FDA ... - Nasdaq
www.nasdaq.com - June 13 at 8:04 AM |
| Seres Therapeutics (MCRB) Commences SER-109 Phase 3 Study in Patients with Multiply Recurrent C. difficile Infection - StreetInsider.com
www.streetinsider.com - June 13 at 8:04 AM |
Seres Therapeutics (MCRB) Chart for Saturday, October, 21, 2017
